Annual Report 2005 - Boehringer Ingelheim

countries since 2000 encourages us to put even
greater emphasis on our efforts to create value
for patients and society. The launch of our new
HIV drug aptivus® in 2005 is thus another step
towards fulfilling our commitment to ‘Value
through Innovation’.
Prescription Medicines, by far our largest busi-
ness area, accounting for 76 % of total net sales,
increased its turnover by more than 17 % to
total EUR 7.2 billion. The share of our product
portfolio which still enjoys patent protection or
exclusivity rights rose to 59 %.
Our other business areas also achieved signifi-
cant growth. In Consumer Health Care (CHC),
our self-medication business, net sales rose
by 8.5 % to almost EUR 1.1 billion. This was
mainly attributable to our flagship brands and
leading products in the cough & cold and gastro-
intestinal indications, such as bisolvon®,
mucosolvan®, dulcolax® and buscopan®.
In addition, pharmaton®, our well-established
international brand for the improvement and
maintenance of vitality and well-being, held the
second strongest position in our CHC product
portfolio.
Members of the Board
of Managing Directors:
Dr Hans-Jürgen Leuchs
Dr Andreas Barner
Dr Alessandro Banchi
Prof. Marbod Muff
(from left to right)
For some years, Boehringer Ingelheim has
been one of the world’s largest manufacturers
of biopharmaceuticals for industrial customers.
We also market our own biotech products,
metalyse® (heart attack) and actilyse® (stroke).
Our overall biopharmaceuticals business,
which grew by 40 % in 2005 to EUR 548 million,
is expected to play an increasingly important
role in combating many major and developing
diseases.
Our Animal Health business, which accounts for
4 % of our net sales, has also grown above the
market average in recent years. In 2005, sales
rose by almost 8 % to EUR 361 million.
A key factor for Boehringer Ingelheim’s sustained
success is our well-distributed presence in all
important world markets. Our products are sold
in some 150 countries. The USA, again by far
the most important market in 2005, generated
36 % of our total net sales. Our US sales grew
by 17 % to EUR 3.4 billion. Japan (+8 % to EUR
1.2 billion) and Europe (+19 % to EUR 3.1 billion)
also posted excellent development. Europe as a
region contributed 33 % of our total net sales.
The healthy business development of the past
business year led to a 40 % rise in operating
income (broadly comparable to EBIT), totalling
EUR 1.9 billion and reflecting an operating
margin of more than 20 %.
Key Aspects of 2005